pharma
Novartis
NovaPharmaNews editorial coverage mentioning Novartis — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Basel, CH
- Programs
- 0
- Drugs
- 0
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Novartis — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Novartis — regulatory, clinical, and market analysis.
EC Approves Itvisma Gene Therapy for SMA 2+
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
Takeda and Novartis Layoffs: Implications for Pharma Industry
Takeda announces a reduction of 4,500 jobs while Novartis lays off biomedical research staff. This article explores the implications for the pharma sector.
Novartis Strengthens Prostate Cancer Treatment with Pluvicto
Novartis has reported stronger PSA responses with its drug Pluvicto in earlier-stage prostate cancer, indicating promising developments in oncology. This news could reshape competitive dynamics in the market.